secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2022-02-10T23:59:59+00:00
Accession:  0000012208-22-000005
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q4 revenue down 7.2% to $733M; GAAP loss $52.59/sh, non-GAAP EPS $3.21; 2022 outlook 1-2% growth
--------------------------------------------------------------------------------

- Q4 2021 sales $732.8M (-7.2% YoY); Life Science sales down 23.8% on lower COVID-related qPCR demand.
- GAAP net loss $1,573.7M ($52.59 loss per diluted share) vs net income $839.1M in Q4 2020, impacted by Sartorius AG fair value changes.
- Non-GAAP net income $97.0M ($3.21 per share) vs $121.0M ($4.01) in Q4 2020.
- Full year 2021 sales $2,922.5M (+14.8% reported); core revenue ex-COVID up 17.0% currency-neutral.
- 2022 guidance: non-GAAP currency-neutral revenue growth 1-2%, non-GAAP operating margin ~19.0%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220822000005/0000012208-22-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220822000005/bio-20220210.htm
  HTML page:      https://secwatch.observer/filing/0000012208-22-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer